Name:
|
Category
|
Manufacturer
|
Clinical Status
& Links
|
4-1BBL
|
T-cell stimulator;
apoptosis inhibitor
|
|
preclinical
|
Anvirzel
|
broad immune
enhancer, believed also to have antiangiogenic effects by some. Oleander
extract
|
|
Phase I trials
|
AS-101
|
broad
immunomodulator increases IL-2 and IL-2 receptor. Organic tellurium salt
|
|
Phase II trials
with Taxol
|
Atragen
Liposomal Tretinoin
|
differentiating
retinoid direct anti-lyphoma/leukemia properties
boosts NK function. More potent than free tretinoin
|
|
phase II trials
lymphoma/leukemia
|
|
|
potent
immunomodulator in bladder cancer, lymphoma,
multiple IFN inducer
|
|
phase III trials
bladder cancer
|
C225
|
Anti-EGFr,
humanized murine,
monoclonal antibody
|
|
Phase III trials
|
CD40 Ligand
|
Dendritic Cell
activator
|
|
phase I
|
Clarithromycin
|
antibiotic,increases
NK counts (best when given a week after chemo)
|
|
approved for H.
Pylori infections
|
CM101
|
potent
antiangiogenic
|
|
Phase I trials
|
Cromolyn
|
Antiallergic,
(mast cell inhibition) anecdotal antiangiogenic properties
|
Medeva
|
approved for
allergies
|
Cytran IM-862
|
very small
protein peptide
anti-angiogenic/
immune stimulating
|
|
phase III
Kaposi's Sarcoma
|
FLT-3 ligand (Mobista)
|
bone marrow
progenitor/dendritic cell growth factor/NK growth factor
|
|
phase II trial
melanoma
|
GM-CSF
(Leukine)
|
leukocyte
proliferative cytokine/dendritic cell promoter. Might enhance Rituxan
|
|
approved for low
white counts
|
hLL2
|
Anti-CD22
humanized murine
monoclonal antibody
|
|
Phase II trials
for NHL
|
Humune
|
Anti-CD20
Completely human
monoclonal antibody
|
Intracell
|
preclinical
|
IDEC-Y2B8
(Zevalin)
|
Yttrium
radiolabled
Anti-CD20;
humanized murine
monoclonal antibody
|
|
approved for
lymphoma
|
IL-12
|
Th1 cytokine
|
|
Phase I-II
|
IL-15
|
promotes NK cells and activates memory T cells
muscle anabolic
|
|
preclinical
|
IL-18
|
Th1 cytokine; Potent Interferon gamma inducer
|
|
investigative
|
IL-2
|
Th1 Cytokine
|
|
Approved renal
cell cancer
Testing in combination with Rituxan for NHL
|
IL-4 receptor (Nuvance)
|
TH2 inhibition
|
|
Phase I trials
Asthma
|
Imiquimod
|
Th1 inducing
pharmaceutical
|
|
Phase I
terminated
|
Interferon Alpha
2b
|
anti-proliferative
MHC I enhancing cytokine
|
|
approved
|
interferon
(peginterferon alfa-2b)
|
as for interferon Alpha 2b, but encapsulated in liposome to reduce
toxicity
|
|
PEG-INF (new version)
improves quality of life - peerviewpress
|
Interferon Gamma
|
Th1 cytokine
|
|
phase I-II
AIDS/cancer
|
IP-10
|
anti-proliferative chemokine;
antiangiogenic T cell attractor
|
|
Phase I using
gene vector in Europe
|
Linomide
|
promotes
TGF-beta,NK cells, inhibits anti-body production.Potent antiangiogenic
|
|
Phase III
Multiple Sclerosis trials terminated due to cardiovascular side effects.
|
|
|
Th1 cytokines; increases NK
activity, increases B cells
|
|
Phase I
|
Product R
(Reticulose)
|
broad immune
enhancer, RNA protein conjugate
|
|
commonly used for
flu throughout the 40's and 50's. removed from market by FDA citing
inadequate research data
|
QS-21
|
broad immune
enhancer. CD8 cell activator. Saponin compound derived from the soapbark
tree Quillaja saponaria
|
Aquila
|
Phase III trials
with vaccine for melanoma. numerous other trials
|
Rituximab/
Rituxan
|
Anti-CD20
Humanized mRNA monoclonal antibody
|
|
approved for
lymphoma
|
SLC
|
chemokine
recently discovered to have potent ant-cancer effects
|
|
investigative
|
Thymosin alpha (Zadaxin)
|
recombinant
thymus peptide. increases IL-2 and IL-2 receptors on T-cells
|
|
Phase II trials
in cancer to start this year, Phase II trials in Hepatitis C ongoing
|
Troponin-1
|
muscle protein
with antiangiogenic effects
|
|
preclinical
|
Ukrain
|
Broad immune
booster. Unusual alkylating agent and plant alkaloid conjugate
|
|
trials in Russia
and Austria
|
Virulizin
|
macrophage
activator, derived from bovine bile
|
|
Phase II trials
pancreatic cancer
|
Z-100
|
cell wall extract
from Mycobacterium Tuberculosis
|
|
clinical trials
in Japan
|
